TrialQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2020

Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial.

Martijn S Visser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.